Compare Citius Pharmaceuticals Inc (CTXR) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs PubMatic Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while PubMatic Inc trades at $13.8 (market cap $635.81M). The key difference: PubMatic Inc is far larger — about 43.4× Citius Pharmaceuticals Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | PUBM | |
|---|---|---|
Market Cap | $14.64M | $635.81M |
Sector | Health | Technology |
52-Week High | $1.82 | $13.83 |
52-Week Low | $0.53 | $6.28 |
Enterprise Value | $10.86M | $533.31M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
PubMatic trades at $13.57, up 0.15% with a bullish technical signal from moving averages. The company reported Q1 2026 earnings that beat expectations despite a net loss, with revenue of $282.93M in 2025 and a gross margin of 63.22%. Recent news highlights partnerships expanding AI-driven ad tech in CTV and international markets, supporting growth initiatives.
Outlook is mixed with strong analyst buy ratings (50%) and a $17.00 consensus target offering 25% upside, but profitability concerns persist with negative net margins and high P/E of 132. Key risks include competitive pressures and reliance on digital ad spending cycles, requiring monitoring of earnings turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
